4.4 Article

Case report: Successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib

期刊

IMMUNITY INFLAMMATION AND DISEASE
卷 11, 期 6, 页码 -

出版社

WILEY
DOI: 10.1002/iid3.897

关键词

Anti-MDA5 antibody; dermatomyositis; interstitial lung disease; JAK inhibitor; tofacitinib

向作者/读者索取更多资源

This study reports a case of anti-MDA5 antibody-positive DM-ILD, in which tofacitinib and tacrolimus were used as treatment options after conventional immunosuppressive therapy and hormone therapy. The patient showed remission of clinical symptoms, reversal of lung imaging tests, and conversion of anti-MDA5 antibody from positive to negative.
ObjectiveAnti-MDA5 antibody-positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti-MDA5-positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1/3 inhibitor tofacitinib as an anti-MDA5-negative treatment option for patients with anti-MDA5-positive DM-ILD. Method and processHere we report a 51-year-old female patient with cough, sputum, shortness of breath for 5 months, rash for 3 months, and muscle pain in the extremities for 1 month. After conventional immunosuppressive therapy plus hormone therapy, the remission was slow. Methylprednisolone was successfully reduced after we administered tofacitinib and tacrolimus. After 132 weeks of follow-up, anti-MDA5 antibody turned negative, clinical symptoms were relieved, and lung Imaging tests were successfully reversed. Results and ConclusionThere is currently no report of tofacitinib supplement therapy for anti-MDA5 positive to negative DM. With this case report, tofacitinib is an option for the treatment of anti-MDA5-positive DM-ILD, which deserves attention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据